Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Gelbfish Gary A.
  2. Issuer Name and Ticker or Trading Symbol
CorMedix Inc. [CRMD]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
C/O CORMEDIX INC., 745 ROUTE 202-206, SUITE 303
3. Date of Earliest Transaction (Month/Day/Year)
01/08/2014
(Street)

BRIDGEWATER, NJ US 08807
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.001 par value per share               474,382 (4) D  
Common Stock, $0.001 par value per share               70,872 (5) I Landmark Foundation (5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series C-3 Non-Voting Convertible Preferred Stock (11) $ 1 01/08/2014   P   30,000     (11)   (11) Common Stock, $0.01 par value per share 300,000 (11) 30,000 D  
Warrant (right to purchase Common Stock) (11) $ 1.25 01/08/2014   P   150,000   01/08/2015(11) 01/08/2020(11) Common Stock, $0.001 par value per share 150,000 (11) 150,000 D  
Series C-3 Non-Voting Convertible Preferred Stock (12) $ 1 01/08/2014   P   20,000     (12)   (12) Common Stock, $0.01 par value per share 200,000 (12) 20,000 I Shares are hed by Gary Gelbfish IRA, Nathaniel Shapiro Trustee (12)
Warrant (right to purchase Comm Stock) (12) $ 1.25 01/08/2014   P   100,000   01/08/2015(12) 01/08/2020(12) Common Stock, $0.001 par value per share 100,000 (12) 100,000 I Shares are held by Gary Gelbfish IRA, Nathaniel Shapiro Trustee (12)
Stock Option (right to buy) $ 0.9               (1) 03/20/2023 Common Stock, $0.001 par value per share 50,000   50,000 D  
Stock Option (right to buy) $ 0.68               (2) 12/05/2022 Common Stock, $0.001 par value per share 70,000   70,000 D  
Warrant (right to purchase Common Stock) (10) $ 0.4             09/20/2012 09/20/2017 Common Stock, $0.001 par value per share 250,000   250,000 D  
Stock Option (right to buy) $ 0.29               (3) 01/06/2022 Common Stock, $0.001 par value per share 30,000   30,000 D  
Stock Option (right to buy) $ 2.1               (6) 01/14/2021 Common Stock, $0.00 par value per share 30,000   30,000 D  
Stock Option (right to buy) $ 3.125               (7) 03/30/2020 Common Stock, $0.001 par value per share 20,000   20,000 D  
8% Noteholder Warrants (8) $ 3.4375               (8) 10/29/2016 Common Stock, $0.001 par value per share 67,200   67,200 D (9)  
8% Noteholder Warrants (8) $ 3.4375               (8) 10/29/2016 Common Stock, $0.001 par value per share 28,800   28,800 I (5) By Landmark Charity Foundation (5)

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Gelbfish Gary A.
C/O CORMEDIX INC.
745 ROUTE 202-206, SUITE 303
BRIDGEWATER, NJ US 08807
  X      

Signatures

 Alexander M. Donaldson, with a Power of Attorney for Gary A. Gelbfish   01/10/2014
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) These options vest quarterly over two years beginning June 30, 2013.
(2) These options vest as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
(3) The options vest in full on the first anniversary of the date of grant.
(4) Includes (i) 94,496 shares of our common stock held jointly by Dr. Gelbfish and his wife, and (ii) 70,872 shares of our common stock held by Dr. Gelbfish as custodian for certain of his children.
(5) Held by Landmark Foundation, of which Dr. Gelbfish and his wife are trustees.
(6) These options vest on January 14, 2012.
(7) These options vest as follows: 1/3 on March 30, 2010; an additional 1/3 on March 30, 2011; and the remaining 1/3 on March 30, 2012.
(8) These warrants became exercisable upon the consummation of the Company's initial public offering.
(9) Includes 8% Noteholder Warrants held by Dr. Gelbfish and his wife jointly, that are exercisable for 38,400 shares of common stock, and 8% Noteholder Warrants held by Dr. Gelbfish as custodian for certain of his children that are exercisable for 28,800 shares of common stock.
(10) On September 20, 2012, the reporting person acquired in a private placement $100,000 of (i) 9% Senior Convertible Notes, convertible into shares of the Company's Common Stock, $0.001 par value per share, at a conversion price of $0.35 per share, which were converted on September 20, 2013; and (ii) a five-year redeemable warrant to purchase common stock at an exercise price of $0.40 per share.
(11) On January 8, 2014, the reporting person acquired in a private placement (i) 30,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share; and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a price of $10.00 per share for each share of Series C-3 Preferred Stock.
(12) On January 8, 2014, the reporting person through his ownership of his IRA account, acquired in a private placement (i) 20,000 shares of the Company's Series C-3 Non-Voting Convertible Preferred Stock, each share is convertible into 10 shares of Common Stock, $0.001 par value per share at a conversion price of $1.00 per share, and (ii) a five-year warrant to purchase common stock at an exercise price of $1.25 per share. The Series C-3 Preferred Stock and the warrants were purchased together at a purchase price of $10.00 per share for each share of Series C-3 Preferred Stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.